LY294002 is a multi-kinase inhibitor. It inhibits casein kinase 2 (CK2, IC50 = 0.098 µM), the PI3K subunits p110alpha, p110beta, p110delta, and p110gamma (IC50s = 0.497, 0.554, 0.331, and 3.8 µM, respectively), and DNA protein kinase (DNA-PK, IC50 = 6 µM), among other kinases, as well as CK1, GSK3alpha, and GSK3beta...

Description: LY294002 (SF 1101) is a broad-spectrum inhibitor of PI3K, inhibiting PI3Kalpha, PI3Kdelta, and PI3Kbeta (IC50=0.5/0.57/0.97 µM). LY294002 is also an inhibitor of DNA-PK (IC50=1.4 µM) and an inhibitor of CK2 (IC50=98 nM). LY294002 activates apoptosis and autophagy. Target: PI3K, Autophagy, Apoptosis,...

Potent, cell permeable, highly specific PI(3)K (phosphoinositide 3-kinase) inhibitor, Acts on the ATP-binding site of the enzyme, Antagonizes P-glycoprotein-mediated multidrug resistance, Blocks Akt phosphorylation, Pim-1 kinase inhibitor.

LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. PI3K is an enzyme that phosphorylates the D-3 position of the inositol ring in phosphoinositides, resulting in the formation of PI(3)P, PI(3,4)P2, and PI(3,4,5)P3. LY294002 is a selective PI3K inhibitor with a 2.7-fold greater potency than quercetin....

LY294002 is an inhibitor of PI3K that is used to sensitize cancer cells to other co-administered anticancer chemotherapeutics. In macrophages and monocytes, LY294002 inhibits NF-kappaB activity and decreases levels of p50 NF-kappaB, it also inhibits LPS-induced expression of IL-10. LY294002 prevents ruffled border...